Merck & Co., Inc. (ETR:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 244.83B +48.7% |
| Revenue (ttm) | 57.04B +2.9% |
| Net Income | 7.75B -48.8% |
| EPS | 3.10 -48.0% |
| Shares Out | n/a |
| PE Ratio | 31.59 |
| Forward PE | 18.54 |
| Dividend | 2.86 (2.90%) |
| Ex-Dividend Date | Mar 16, 2026 |
| Volume | 492 |
| Open | 98.64 |
| Previous Close | 98.46 |
| Day's Range | 98.04 - 99.16 |
| 52-Week Range | 66.00 - 106.00 |
| Beta | 0.20 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock produ... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial numbers in USD Financial StatementsNews
Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference.
Merck & Co. Transcript: Investor update
Significant progress was highlighted in oncology, with KEYTRUDA's expansion into earlier-stage indications, a diversified late-stage pipeline, and strong clinical data for sac-TMT and other novel assets. Commercial momentum is robust, with new launches and a projected $25B+ opportunity by the mid-2030s.
Merck & Co. Press release: Investor update
Merck & Co. issued a press release on June 1, 2026, disclosing material business information to investors.
Merck & Co. Slides: Investor update
Merck & Co. has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Merck exec says company is discussing use of COVID antiviral drug in Ebola response
Merck is in discussions with various global health authorities about making its COVID antiviral pill molnupiravir available as an Ebola treatment to address the widening outbreak in the Democratic Re...
Moderna, Merck to present 5-year data for intismeran autogene
Moderna (MRNA) and Merck (MRK), known as MSD outside of the United States and Canada, announced detailed results from a planned five-year follow-up analysis of the Phase 2b randomized KEYNOTE-942/mRNA...
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurr...
Merck says FDA grants Breakthrough Therapy Designation for calderasib
Merck (MRK) announced that calderasib, an investigational oral specific KRAS G12C inhibitor, in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, has been granted Breakthrough Therapy designation ...
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that calderasib (MK-1084), an investigational oral specific KRAS G12C in...
Merck to Participate in the Jefferies Global Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Jefferies Global Healthcare Conference.
Merck and Mastercard are seeing real agentic AI results. Both say the plumbing came first.
Merck is using AI agents to cut drug discovery cycles by a third and ship compliant marketing materials up to 80% faster — but VP of Digital Platforms Sean Finnerty says the only reason it's working i...
Merck chicken bronchitis vaccine approved for use in China
Merck said its vaccine against bronchitis in chickens has been approved by the Chinese agriculture ministry for use in the world's largest chicken-rearing country, which is home to over 5 billion ...
Merck Announces Third-Quarter 2026 Dividend
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Third-Quarter 2026 Dividend.
Merck & Co. Transcript: AGM 2026
The meeting highlighted strong financial growth, a robust late-stage pipeline, and major investments in R&D and manufacturing. All board nominees and management proposals were approved, while shareholder proposals on DEI, healthcare coverage, and political contributions were not.
Merck & Co. Slides: FY 2026
Merck & Co. has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 26, 2026.
Merck stock jumps as Keytruda combo trials boost cancer pipeline
Shares of Merck & Co. (MRK) rose 5% on Friday after the pharmaceutical giant reported positive developments across multiple oncology programs, reinforcing investor confidence in its efforts to extend ...
Merck Stock Climbs on Cancer Data. Why the Drugmaker Is More Than a One-Trick Pony.
Merck shares rose after partner Kelun-Biotech reported positive late-stage trial results for a Keytruda combination treatment in lung cancer.
Merck receives positive CHMP opinion for KEYTRUDA plus Padcev
Merck (MRK) announced the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of KEYTRUDA, Merck’s anti-PD-1 therapy, in combina...
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Human Use (...
Kelun, Merck's lung cancer combo improves survival in late-stage China trial
Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment combined with partner Merck's Keytruda improved survival rate in patients with advanced lung cancer, meeting the ma...
Moderna, Merck cancer combo cuts melanoma spread risk at five years
Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another part of the body by 59% after five years of follow-up, data from a mid-stage trial showed Th...
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
DARMSTADT, Germany--(BUSINESS WIRE)--Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer.
National Advertising Review Board Refers Merck Animal Health to FTC and FDA for Bravecto Quantum Dosing Claims
A panel of the National Advertising Review Board (NARB), the appellate advertising body of BBB National Programs, has referred Intervet, Inc. (d/b/a Merck Animal Health) to the Federal Trade Commissio...
Exelixis announces clinical development collaboration with Merck
Exelixis (EXEL) announced that the company has entered into a clinical development collaboration with Merck (MRK), known as MSD outside of the United States and Canada, to supply Keytrude Qlex…
Merck’s Sac-TMT met primary endpoints in endometrial cancer trial
Merck (MRK) announced the pivotal Phase 3 TroFuse-005 trial evaluating sacituzumab tirumotecan, or sac-TMT, an investigational TROP2-directed antibody-drug conjugate, or ADC, being developed in collab...